Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Dilman VM: Metabolic immunodepression which increases the risk of cancer. Lancet2(8050),1207–1209 (1977).▪▪ Important paper that describes mechanisms of associations between cancer risk and hormonal-metabolic disturbances and the need of the latter elimination.
  Medline CASGoogle Scholar
• 2  Breslow L, Agran L, Breslow DM, Morganstern M, Ellwein L: Cancer control: implications from its history. J. Natl Cancer Inst.59(2 Suppl.),671–686 (1977).
  Medline CASGoogle Scholar
• 3  Lowe J: The Metabolic Treatment of Fibromyalgia. McDowell Publishing, Lafayette, CO, USA, 312 (2000).
  Google Scholar
• 4  Dilman VM: Endocrinological Oncology. Meditsina, Leningrad, Russia (1983).
  Google Scholar
• 5  Dilman VM, Berstein LM, Tsyrlina EV et al.: On correction of hormonal-metabolic disturbances in oncological patients. Effect of biguanides (phenformin and adebit), misclerone and diphenin. Vopr. Onkol.21(11),33–39 (1975).▪ First paper on metabolic rehabilitation of oncological patients presenting own data.
  CASGoogle Scholar
• 6  Dilman VM, Ryabov SI, Tsyrlina EV et al.: Reduction of body weight, cholesterol and glucose level under influence of metformin in patients with cancer and atherosclerosis. Vopr. Onkol.18(2),84–86 (1972).
  CASGoogle Scholar
• 7  Dilman VM: Aging, Climax and Cancer. Meditsina, Leningrad, Russia (1968).
  Google Scholar
• 8  Dilman VM, Berstein LM, Ostroumova MN et al.: Metabolic immunodepression and metabolic immunotherapy. An attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances. Oncology39,13–19 (1982).▪ Important paper that describes mechanisms of associations between cancer risk and hormonal-metabolic disturbances and the need of the latter elimination.
  Medline CASGoogle Scholar
• 9  Dilman VM, Berstein LM, Yevtushenko TP et al.: Preliminary evidence on metabolic rehabilitation of cancer patients. Arch. Geschwulstf58,175–183 (1988).▪ The summary of metabolic rehabilitation results by the time of publication.
  Medline CASGoogle Scholar
• 10  Dilman V, Dean W: The Neuroendocrine Theory of Aging and Degenerative Disease. The Center for Bio-Gerontology, Pensacola, FL, USA (1992).
  Google Scholar
• 11  Berstein LM, Yevtushenko TP, Tsyrlina EV et al.: Comparative study of 5- and 10-years results of metabolic rehabilitation of oncological patients. In: Neuroendocrine System, Metabolism, Immunity and Cancer. Hanson KP, Dilman VM (Eds). NN Petrov Research Institute of Oncology Publ, St Petersburg, Russia, 102–112 (1992).
  Google Scholar
• 12  Berstein LM, Santen RJ (Eds): Innovative Endocrinology of Cancer. Landes Bioscience, Springer Science+Business Media, TX, USA (2008).
  Google Scholar
• 13  MacMahon B: Overview of studies on endometrial cancer and other types of cancer in humans: perspectives of an epidemiologist. Semin. Oncol.24(1 Suppl. 1),S1–S39 (1997).
  Medline CASGoogle Scholar
• 14  Berstein LM: Oncoendocrinology: Traditions, contemporary situation and perspectives. Nauka Publishers, St Petersburg, Russia (2004).
  Google Scholar
• 15  Barnadas A, Gil M, Sanchez-Rovira P: Neoadjuvant endocrine therapy for breast cancer: past, present and future. Anti-Cancer Drugs19,339–347 (2009).
  Google Scholar
• 16  Miller WR: Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer. J. Steroid Biochem. Mol. Biol.118(4–5),273–276 (2010).
  Medline CASGoogle Scholar
• 17  Semiglazov VF, Semiglazov VV, Dashyan GA et al.: Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer110(2),244–254 (2007)
  Medline CASGoogle Scholar
• 18  Bokhman JV, Chepick OF, Volkova AT, Vishnevsky AS: Can primary endometrial carcinoma stage I be cured without surgery and radiation therapy? Gynecol. Oncol.20(2),139–155 (1985).
  Medline CASGoogle Scholar
• 19  Yamazawa K, Hirai M, Fujito A: Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum. Reprod.22(7),1953–1958 (2007).
  Medline CASGoogle Scholar
• 20  Blagosklonny MV: Prevention of cancer by inhibiting aging. Cancer Biol. Ther.7,1520–1524 (2008).▪ Demonstrates approaches that address systemic and cellular targets.
  Medline CASGoogle Scholar
• 21  Berstein LM: Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Lett.224(2),203–212 (2005).▪ Overview of existing and own data by the publication time.
  Medline CASGoogle Scholar
• 22  Liao JK: Clinical implications for statin pleiotropy. Curr. Opin. Lipidol.16(6),624–629 (2005).
  Medline CASGoogle Scholar
• 23  Zhou G, Myers R, Li Y et al.: Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest.108(8),1167–1174 (2001).
  Medline CASGoogle Scholar
• 24  Rose DP, Vona-Davis L: Influence of obesity on breast cancer receptor status and prognosis. Expert Rev. Anticancer Ther.9(8),1091–1101 (2009).
  Medline CASGoogle Scholar
• 25  Ruhstaller T, von Moos R, Rufibach K et al.: Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study. Oncology76,142–148 (2009).
  MedlineGoogle Scholar
• 26  Yue W, Fan P, Wang J, Li Y, Santen RJ: Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J. Steroid Biochem. Mol. Biol.106,102–110 (2007).
  Medline CASGoogle Scholar
• 27  Musgrove EA, Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer9,631–643 (2009).
  Medline CASGoogle Scholar
• 28  Saylor PJ, Smith MR: Metabolic complications of androgen deprivation therapy for prostate cancer. J. Urol.181,1998–2008 (2009).▪ Interesting summary devoted to an important problem.
  Medline CASGoogle Scholar
• 29  Heideman WH, Russell NS, Gundy C, Rookus MA, Voskuil DW: The frequency, magnitude and timing of post-diagnosis body weight gain in Dutch breast cancer survivors. Eur. J. Cancer45,119–126 (2009).
  Medline CASGoogle Scholar
• 30  McCourt CK, Mutch DG, Gibb RK et al.: Body mass index: relationship to clinical, pathologic characteristics and features of microsatellite instability in endometrial cancer. Gynecol. Oncol.104,535–539 (2007).▪ Important study connecting DNA repair defects with hormonal-metabolic disturbances in cancer patients.
  MedlineGoogle Scholar
• 31  Golubev AG: The other side of metabolism. Biokhimiia (Moscow)61(11),2018–2039 (1996).
  Medline CASGoogle Scholar
• 32  Unoki H, Yamagishi S: Advanced glycation end products and insulin resistance. Curr. Pharm. Des.14(10),987–989 (2008).
  Medline CASGoogle Scholar
• 33  van Kruijsdijk RC, van der Wall E, Visseren FL: Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol. Biomarkers Prev.18(10),2569–2578 (2009).
  Medline CASGoogle Scholar
• 34  Warburg O: On the origin of cancer cells: 30 years of research. Science123,309–314 (1956).
  Medline CASGoogle Scholar
• 35  Shaw RJ: Glucose metabolism and cancer. Curr. Opin. Cell Biol.18,598–608 (2006).▪▪ Excellent review on multifaceted associations between glucose and cancer.
  Medline CASGoogle Scholar
• 36  DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB: The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell. Metab.7(1),11–20 (2008).
  Medline CASGoogle Scholar
• 37  Gogvadze V, Orrenius S, Zhivotovsky B: Mitochondria in cancer cells: what is so special about them. Trends Cell. Biol.18,165–173 (2008).
  Medline CASGoogle Scholar
• 38  Shackelford DB, Shaw RJ: The LKB1–AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer9(8),563–575 (2009).▪▪ Excellent overview of connection in LKB1–adenosine monophosphate-activated protein kinase (AMPK) tandem with an analysis of the data on AMPK activators including metformin.
  Medline CASGoogle Scholar
• 39  Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res.69,7507–7511 (2009).
  Medline CASGoogle Scholar
• 40  Stearns V, Rae JM: Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? Expert Rev. Mol. Med.10,E34 (2008).
  MedlineGoogle Scholar
• 41  Aquilante CL: Pharmacogenetics of thiazolidinedione therapy. Pharmacogenomics8(8),917–931 (2007).▪ Comprehensive example of this area of importance.
  CASGoogle Scholar
• 42  Reitman ML, Schadt EE: Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J. Clin. Invest.117(5),1226–1229 (2007).▪ Another example of this area of importance.
  Medline CASGoogle Scholar
• 43  Berstein LM: Role of endocrine-genotoxic switchings in cancer and other human diseases: basic triad. Adv. Exp. Med. Biol.630,35–51 (2008).
  Medline CASGoogle Scholar
• 44  Bershtein LM, Tsyrlina EV, Kovalevskii AI et al.: Endocrine-genotoxic switchings as promoter of main noninfectious diseases. Vestn. Ross. Akad. Med. Nauk.1,12–18 (2008) [in Russian].
  Google Scholar
• 45  Berstein LM: Endocrinology of the wild and mutant BRCA1 gene and types of hormonal carcinogenesis. Future Oncol.4(1),23–39 (2008).
  CASGoogle Scholar
• 46  Eliassen AH, Hankinson SE: Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv. Exp. Med. Biol.630,148–165 (2008).
  Medline CASGoogle Scholar
• 47  Neilson HK, Friedenreich CM, Brockton NT, Millikan RC: Physical activity and postmenopausal breast cancer: proposed biologic mechanisms and areas for future research. Cancer Epidemiol. Biomarkers Prev.18(1),11–27 (2009).
  Medline CASGoogle Scholar
• 48  Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer8,915–928 (2008).
  Medline CASGoogle Scholar
• 49  Sjöström L, Gummesson A, Sjöström CD et al.: Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol.10,653–662 (2009).▪▪ Milestone paper on effect of bariatric surgery as a preventive measure.
  MedlineGoogle Scholar
• 50  Vigersky RA, Filmore-Nassar A, Glass AR: Thyrotropin suppression by metformin. J. Clin. Endocrinol. Metab.91,225–227 (2006).
  Medline CASGoogle Scholar
• 51  Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG: Insulin-lowering effects of metformin in women with early breast cancer. Clin. Breast Cancer8,501–505 (2008).▪ Interesting paper of the experienced expert in metformin and cancer area.
  Medline CASGoogle Scholar
• 52  Demark-Wahnefried W, Rock CL, Patrick K, Byers T: Lifestyle interventions to reduce cancer risk and improve outcomes. Am. Fam. Physician77(11),1573–1578 (2008).
  MedlineGoogle Scholar
• 53  Pan SY, DesMeules M: Energy intake, physical activity, energy balance, and cancer: epidemiologic evidence. Methods Mol. Biol.472,191–215 (2009).
  MedlineGoogle Scholar
• 54  Yeh HC, Duncan BB, Schmidt MI, Wang NY, Brancati FL: Diabetes and quitting of smoking. Ann. Intern. Med.152,10–17 (2010).
  MedlineGoogle Scholar
• 55  Patterson RE, Cadmus LA, Emond JA, Pierce JP: Physical activity, diet, adiposity and female breast cancer prognosis: a review of the epidemiologic literature. Maturitas66(1),5–15 (2010).
  MedlineGoogle Scholar
• 56  Bernstein L: Identifying population-based approaches to lower breast cancer risk. Oncogene27(Suppl. 2),S3–S8 (2008).▪▪ Paper of notable importance summarizing author’s experience and views on the role of physical activity and other healthy lifestyle approaches.
  Medline CASGoogle Scholar
• 57  Schernthaner G: Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. Int. J. Clin. Pract.63,912–929 (2009).
  Medline CASGoogle Scholar
• 58  Mann D, Reynolds K, Smith D, Muntner P: Trends in statin use and low-density lipoprotein cholesterol levels among US Adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann. Pharmacother.42(9),1208–1215 (2008).
  Medline CASGoogle Scholar
• 59  Alimova IN, Liu B, Fan Z et al.: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle8,909–915 (2009).
  Medline CASGoogle Scholar
• 60  Anisimov VN, Berstein LM, Egormin PA et al.: Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp. Gerontol.40,685–693 (2005).
  Medline CASGoogle Scholar
• 61  Campbell MJ, Esserman LJ, Zhou Y et al.: Breast cancer growth prevention by statins. Cancer Res.66,8707–8714 (2006).
  Medline CASGoogle Scholar
• 62  Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res.67,10804–10812 (2007).
  Medline CASGoogle Scholar
• 63  Chong CR, Chabner BA: Mysterious metformin. Oncologist14,1178–1181 (2009).▪ Important paper underlining positive effects of metformin and the need of resurrecting of phenformin.
  Medline CASGoogle Scholar
• 64  Huang X, Wullschleger S, Shpiro N et al.: Important role of the LKB1–AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem. J.412(2),211–221 (2008).
  Medline CASGoogle Scholar
• 65  Zhou Z, Rahme E, Pilote L: Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am. Heart J.151,273–281 (2006).
  Medline CASGoogle Scholar
• 66  Kuoppala J, Lamminpää A, Pukkala E: Statins and cancer: a systematic review and meta-analysis. Eur. J. Cancer44,2122–2132 (2008).▪ Paper of importance accentuating complexity of the problem.
  Medline CASGoogle Scholar
• 67  Garwood ER, Kumar AS, Baehner FL et al.: Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res. Treat.119,137–144 (2010).
  Medline CASGoogle Scholar
• 68  Yu HN, Noh EM, Lee YR et al.: Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells. Biochem. Biophys. Res. Commun.377,242–247 (2008).
  Medline CASGoogle Scholar
• 69  Ramos-Nino ME, MacLean CD, Littenberg B: Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Med.5,17 (2007).
  MedlineGoogle Scholar
• 70  Rodríguez-Enríquez S, Marín-Hernández A, Gallardo-Pérez JC, Carreño-Fuentes L, Moreno-Sánchez R: Targeting of cancer energy metabolism. Mol. Nutr. Food Res.53,29–48 (2009).
  Medline CASGoogle Scholar
• 71  Menendez JA, Vellon L, Lupu R: The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells. Int. J. Gynecol. Cancer16,219–221 (2006).
  Medline CASGoogle Scholar
• 72  Chow LW, Loo WT, Toi M: Current directions for COX-2 inhibition in breast cancer. Biomed. Pharmacother.59(Suppl. 2),S281–S284 (2005).
  Medline CASGoogle Scholar
• 73  Zhang MZ, Xu J, Yao B et al.: Inhibition of 11b-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans. J. Clin. Invest.119(4),876–885 (2009).
  Medline CASGoogle Scholar
• 74  Gibbons JJ, Abraham RT, Yu K: Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin. Oncol.36(Suppl. 3),S3–S17 (2009).
  Medline CASGoogle Scholar
• 75  Athar M, Back JH, Tang X et al.: Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol.224,274–283 (2007).
  Medline CASGoogle Scholar
• 76  Saiah E: The role of 11β-hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11 β-HSD1 inhibitors. Curr. Med. Chem.15,642–649 (2008).
  Medline CASGoogle Scholar
• 77  Macciò A, Madeddu C, Mantovani G: Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives. Obes. Rev.10,660–670 (2009).▪ Comprehensive paper important for metabolic rehabilitation problem.
  Medline CASGoogle Scholar
• 78  Bozzetti F, Mori V: Nutritional support and tumour growth in humans: a narrative review of the literature. Clin. Nutr.28,226–230 (2009).
  Medline CASGoogle Scholar
• 79  Chlebowski RT, Blackburn GL, Thomson CA et al.: Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J. Natl Cancer Inst.98,1767–1776 (2006).▪ Paper of notable importance summarizing author’s experience.
  MedlineGoogle Scholar
• 80  Thomson CA, Thompson PA: Dietary patterns, risk and prognosis of breast cancer. Future Oncol.5,1257–1269 (2009).
  Google Scholar
• 81  Chan AT, Giovannucci EL: Primary prevention of colorectal cancer. Gastroenterology138(6),2029–2043.E10 (2010).
  Medline CASGoogle Scholar
• 82  Thompson PA, Gerner EW: Current concepts in colorectal cancer prevention. Expert Rev. Gastroenterol. Hepatol.3(4),369–382 (2009).
  MedlineGoogle Scholar
• 83  Atiomo W, Read A, Golding M et al.: Local recruitment experience in a study comparing the effectiveness of a low glycaemic index diet with a low calorie healthy eating at achieving weight loss and reducing the risk of endometrial cancer in women with polycystic ovary syndrome. Contemp. Clin. Trials30,451–456 (2009).
  MedlineGoogle Scholar
• 84  Oliveria SA, Koro CE, Yood MU, Sowell M: Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metabol. Syndrome Clin. Res. Rev.2,47–57 (2008).
  Google Scholar
• 85  Garwood ER, Kumar AS, Baehner FL et al.: Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res. Treat.119,137–144 (2010).
  Medline CASGoogle Scholar
• 86  Bowker SL, Majumdar SR, Veugelers P, Johnson JA: Increased cancer-related mortality for patients with Type 2 diabetes who use sulfonylureas or insulin. Diabetes Care29,254–258 (2006).
  MedlineGoogle Scholar
• 87  Currie CJ, Poole CD, Gale EA: The influence of glucose-lowering therapies on cancer risk in Type 2 diabetes. Diabetologia52,1766–1777 (2009).▪▪ Excellent analysis of recently published data.
  Medline CASGoogle Scholar
• 88  Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM: New users of metformin are at low risk of incident cancer: a cohort study among people with Type 2 diabetes. Diabetes Care32,620–625 (2009).
  Google Scholar
• 89  Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA: If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials. J. Clin. Oncol.27,E207–E209 (2009).
  Medline CASGoogle Scholar
• 90  Berstein LM: Metformin, insulin, breast cancer and more… Future Oncol.5,309–312 (2009).
  CASGoogle Scholar
• 91  Berstein LM, Kvatchevskaya JO, Poroshina TE et al.: Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer. J. Cancer Res. Clin. Oncol.130,687–693 (2004).
  Medline CASGoogle Scholar
• 92  Ooi M, Kotoula V, Charalambous E: The antidiabetic biguanide metformin induces growth arrest in thyroid carcinoma cells in vitro. Presented at: Proc. 91th Annual Endocrine Soc. (USA)P2.521 (2009).
  Google Scholar
• 93  Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump V: Metformin is a potent inhibitor of endometrial cancer cell proliferation – implications for a novel treatment strategy. Gynecol. Oncol.116,92–98 (2010).
  Medline CASGoogle Scholar
• 101  Clinical trials.gov: metformin, glitazones and cancer www.ClinicalTrials.gov (Accessed 21 January 2010)▪ Important site presenting information on clinical trials recently started with mentioned compounds.
  Google Scholar
• 102  Lloyd RS: DNA repair deficiency associated with obesity and the metabolic syndrome Report on NIH (USA) grant 1R01DK075974–01A2, 2009–2014 www.researchprofiles.collexis.com/ohsuv3/grantDetail (Accessed 14 January 2010)
  Google Scholar